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Polymyositis/dermatomyositis: the current position
A Urbano-Mairquez, Jordi Casademont, Josep M Grau
Polymyositis/dermatomyositis are a hetero-
geneous group of diseases characterised by
skeletal muscle inflammation and necrosis.' 2
Since an excellent clinical description in 1903 by
Steiner of dermatomyositis, which is essentially
still valid,3 much progress has been made
towards our understanding of this group of
diseases. The most widely used clinical classifi-
cation of idiopathic inflammatory myopathies is
the one proposed by Bohan and Peter in 1975.4
That was a landmark, providing guidelines in
clinical practice to accurate diagnosis of inflam-
matory myopathies and standardisation of
studies. Nonetheless, the classification was
based on clinical data. In view of recent
histological and immunological studies the clas-
sification proposed by Karpati et al in 1987
seems better to fit our current view of such
diseases5 (table 1). In this review we focus on
recent developments in polymyositis/dermato-
myositis, analysing separately the currently
considered third major form of inflammatory
myopathy-inclusion body myositis.
Epidemiology
Polymyositis/dermatomyositis are the most
commonly acquired myopathies in developed
countries6 if we do not consider subclinical
forms of toxic myopathies,7 but still fairly
uncommon. No more than 5-10 new cases per
million persons per year are diagnosed in the
United States.8 We have found a similar inci-
dence in a large teaching hospital with dermato-
logical clinic and muscle research unit. Never-
theless, the true incidence of polymyositis/
dermatomyositis remains unknown for several
reasons. Firstly, some patients with dermato-
myositis are currently treated by their general
practitionerbecause diagnosis is 'easy'. Secondly,
some cases of polymyositis may have such an
indolent clinical course that diagnosis is only
made when a muscle biopsy is performed; some
patients with polymyositis undergo diagnostic
muscle biopsy after persistently raised serum
creatine kinase activity with minimal or no
clinical symptoms. Thirdly, there are few or no
prospective studies of connective tissue disease
associated myositis; fourthly, not all laboratories
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use the different microscope techniques re-
quired to diagnose entities such as inclusion
body myositis. There are striking differences
between the prevalences of the three major
forms of idiopathic inflammatory myopathies
reported by different authors.6 9-42 Probably,
dermatomyositis is the most prevalent form, but
in reference centres, from where epidemiological
data are usually obtained, other less well known
entities, such as inclusion body myositis, are
relatively more prevalent. Experience with
idiopathic inflammatory myopathies in a single
institution rarely exceeds 100 cases and thus
multicentre studies are mandatory to achieve
better knowledge about epidemiology, clinical
manifestations, and therapeutic approaches.
Considered as a whole group, polymyositis/
dermatomyositis are more common in women
than in men (3:1). A higher incidence has been
reported in black women. Polymyositis/
dermatomyositis are seen in all ages with two
peaks of incidence-one in the first decade of
life and the other in the fifth to sixth decade.
Seasonal variation in the onset of polymyositis/
dermatomyositis has been noted, suggesting
that environmental factors may affect the
development of the disease.'3
The association of polymyositis/dermato-
myositis with cancer remains controversial.'4 15The incidence of cancer ranges from 10 to 70%
in different series, but in most studies the
patients selected were not a sufficiently homo-
geneous group for definite conclusions to be
reached. Attempts to identify patients with
myositis at risk for developing cancer have been
unsuccessful.'6 17 Our current position is to
consider at risk patients over 50 years, particu-
larly men, with typical or no cutaneous lesions
but who exhibit capillary damage at muscle
biopsy. In such patients a careful clinical
history, physical examination, search for occult
blood in stools, routine chemistry and haema-
tology tests, and abdominal ultrasound examin-
ation are the first step in clinical evaluation. The
submission of patients to an exhaustive search
for an occult neoplasia seems disproportionate.
Pathogenic mechanisms
Two major pathogenic mechanisms probably
lead to polymyositis/dermatomyositis-namely,
capillary muscle damage and lymphocyte and
macrophage mediated cytotoxicity, each, in
turn, affecting patients with dermatomyositis
and polymyositis to a different degree. Several
authors have shown the unequivocal and con-
stant capillary damage in muscle tissue from
patients with dermatomyositis,l 18 19 even as an
early pathological feature.20 Deposition of C5b9
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(membrane attack complex) has also been
reported in the capillary bed of patients with
dermatomyositis.' The presence of undulating
tubules in the endothelial cells is of great value
in the diagnosis of dermatomyositis. Ischaemia
may be the cause of muscle changes, such as
microinfarcts, focal loss of myofibrils, and
perifascicular atrophy, all characteristic of
biopsy specimens from patients with dermato-
myositis.
In polymyositis there is no evidence for
muscle ischaemia. Lymphocyte and macro-
phage mediated cytotoxic damage seem to cause
muscle cell injury, as suggested by immuno-
histochemical22 23 and ultrastructural24 studies.
Recent papers have shown a strong expression
of class I products of the major histocompati-
bility complex (MHC) in the sarcolemma of
most polymyositis muscle cells, especially in the
non-necrotic partially invaded cells, in contrast
with dermatomyositis biopsy specimens, in
which MHC I proteins are only expressed in
atrophic cells of the perifascicular areas and
in regenerating fibres.25 This suggests that in
polymyositis there is a cell mediated immune
response against the muscle cell due to sensiti-
sation to a surface associated antigen or to an
antigen cross reactive with a component of the
fibre surface.
Although the factors that lead to capillary
damage and class I MHC expression in muscle
cells are not known, viral triggering is possible
as occurs in other virus related myopathies such
as HIV.26 Thus Bowles et al used reverse
transcription to show the presence of coxsackie-
virus B RNA in four of seven dermatomyositis
and one of two polymyositis muscle tissues but
found none in controls.27 Serological evidence
for coxsackievirus B infection has also been
published by Christensen et al.28 Other factors
have been suggested, but the causative agents of
polymyositis/dermatomyositis remain unknown.
A better knowledge of the different pathogenic
mechanisms would enable more rational treat-
ment with the diverse immunomodulators
available.29
Clinical picture
The major clinical feature of polymyositis/
dermatomyositis is weakness. Far less common
are tenderness and spontaneous muscle pain. In
dermatomyositis muscle pain is commonly
induced by exercise.' Atrophy and contractures
appear late in the course of the disease. Some-
times, muscular calcifications may develop
later, especially in childhood forms. The
proximal muscles of the legs are usually the first
affected, followed by the proximal arm muscles
and the trunk. The presence or absence of
capillary damage establishes two subgroups of
inflammatory myopathies with different disease
chronicity. The presence of capillary damage
(dermatomyositis) is associated with a more
acute form of the disease, with a mean time
from the onset ofsymptoms to diagnosis ofabout
10 weeks, whereas in the absence of capillary
damage (polymyositis) the mean time from
onset to diagnosis is about 25 weeks.30 Skin
manifestations are the foremost criteria to differ-
entiate dermatomyositis from polymyositis. The
only pathognomonic lesions are the heliotrope
discoloration over the upper eyelid and the
Gottron erythema over the knuckles.3' About
15% of patients with dermatomyositis do not
present with these typical lesions, however.32
There are other dermatological changes-subtle
rashes occasionally in a photosensitive distri-
bution, vasculitic changes at the bases of the
nails, and cuticular overgrowth-that make it
difficult to differentiate between polymyositis
and dermatomyositis on clinical grounds.
The most common gastrointestinal disorder is
dysphagia. It is found clinically in about one
third of patients with dermatomyositis, being
more rare in polymyositis. It may complicate
severe cases, possibly with nasal regurgitation
and aspiration.33 34 It is usually due to crico-
pharyngeal striated muscle weakness, though
oesophageal dysfunctionmay also occur. Delayed
gastric emptying and decreased intestinal
motility are more rarely found, suggesting a
malfunction of the smooth muscle in these
diseases.35
Cardiac disease is occasionally seen in derma-
tomyositis but is rare in polymyositis. It presents
as unspecific electrocardiographic changes,
though arrhythmias, bundle branch blocks,
pericarditis, and even congestive heart failure
have been described.36 37 Some studies have
found cardiac disease to be an important prog-
nostic factor.36
Arthralgia is common in dermatomyositis,
whereas overt arthritis is rare. The affected
joints are usually the small ones of the hands
and wrists, but shoulders and knees may also be
affected. Arthralgia is not a feature of poly-
myositis, being found only when associated
with interstitial lung disease.38 39 Raynaud's
phenomenon is often present when polymyositis
is associated with other collagen vascular
diseases. "
An important systemic manifestation is pul-
monary disease. Aspiration pneumonia, hypo-
ventilation due to muscle weakness, opportunis-
tic infections, and drug related pulmonary
infiltrates may be found, but the most charac-
teristic clinical picture is interstitial lung
disease.Y "' It affects 5 to 10% of patients with
myositis and presents as non-productive cough,
dyspnoea, and hypoxaemia. Radiologically,
interstitial lung disease is indistinguishable from
idiopathic pulmonary fibrosis. The histological
findings in polymyositis/dermatomyositis as-
sociated with interstitial lung disease cover a
wider field than previously suspected and
include some forms of bronchiolitis obliterans
organising pneumonia and diffuse alveolar
damage.42 We have found it to be associated
equally with the presence or absence of skin
manifestations, but muscle capillary lesions are
always present. Fortunately, most cases of
interstitial lung disease are responsive to
immunosuppressive treatment.43
Diagnosis
To diagnose polymyositis/dermatomyositis it is
mandatory to rule out other inflammatory
myopathies of known cause and other clinical
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Table 2 Differential diagnoses in idiopathic inflammatory
myopathies
Polymyalgia rheumatica
Endocrine myopathies (particularly hypothyroid)
Necrotising myopathy associated with cancer
Mitochondrial myopathy (adult onset)
Trichinosis
HIV myopathy (with orwithout concurrent zidovudine treatment)
Eosinophilia myalgia syndrome
McArdle's disease and other storage diseases
Chronic fatigue syndrome
conditions that can mimic idiopathic inflam-
matory myopathy (table 2). Polymyositis/
dermatomyositis and even the particular form of
it may be suspected on clinical grounds, but
further investigations are always required to
confirm the diagnosis. The most widely
accepted diagnostic criteria are those originally
proposed by Bohan and Peter4 and modified by
Hudgson and Peter" based on a compatible
clinical picture, raised creatine kinase activity,
multifocal electromyographic changes of
'myositis', and biopsy evidence of necrosis and
inflammation. When all four criteria are satisfied
a diagnosis of definite idiopathic inflammatory
myopathy can be made. The presence of three
or two criteria allows the diagnosis of probable
and possible idiopathic inflammatory myopathy
respectively. Probably not all the criteria should
be given the same weight as the defmnition of
polymyositis/dermatomyositis is based on histo-
pathological criteria.' 2 We believe that the
biopsy findings are of great importance in
establishing the diagnosis. Without them the
diagnosis will always be questionable, whereas
with a biopsy defmiite forms can be diagnosed
even in the absence of more than one of the
other criteria. Among the 'muscle enzymes'
creatine kinase activity is the most sensitive and
useful biochemical determination.45 It is usually,
but not invariably, raised during the active
phase of disease. Immunological studies such as
rheumatoid factor, immunoglobulins, comple-
ment, and antinuclear antibodies are of little
value in the diagnosis and management of any
form of polymyositis/dermatomyositis. The
exception is the Jo-I antibody, an antinuclear
antibody clearly related to the presence of
interstitial lung disease.i' 4 The significance of
the antiendothelial antibodies, taking into
account the importance of capillary damage as a
causative factor of dermatomyositis, is not yet
completely understood.48
Electromyographic findings in dermato-
myositis may be normal in about 10% of
patients, or even more patients if the sample is
not wide, owing to the multifocal nature of this
Table 3 Salient distinctive pathologicalfeatures ofpolymyositis/dermatomyosttis (PM/DM)
and inclusion body myositis (IBM)
DM PM IBM
Perifascicular atrophy + - -
Capillary damage + -
Lined vacuoles - - +
Ragged-red fibres - +
Partial invasion - + +
Cellular infiltration (predominant) B Perivascular T Endomisial T Endomisial
MHC* class I expression + Perifascicular + +
Cb9 in vessels +
*MHC=major histocompatibility complex.
disease. Electromyography is not a good test for
assessing disease activity or for establishing
differences between the different forms of
polymyositis/dermatomyositis.49 Muscle scinti-
graphy after administration of 99ITc labelled
phosphate complexes, ultrasonography, com-
puted tomography, and magnetic resonance
imaging are of limited value for diagnostic
purposes but may be useful in identifying the
site of biopsy.50
Muscle biopsy is indispensable for the diag-
nosis of polymyositis/dermatomyositis. If proper
techniques are used a distinction between the
different forms is easily accomplished. We
believe that biopsy is always indicated for
adults. The biopsy must be done on affected but
not wasted muscle, and by sensitised personnel.
The convenience of an open biopsy is debatable.
We performed simultaneous open and needle
biopsies on 13 patients, and the diagnostic yield
was the same. The advantages of an open biopsy
are a better sample, better orientation, and the
possibility of studying different areas of the
same specimen-particularly useful in focal
diseases such as dermatomyositis. We only use
needle biopsies for follow up of patients.
Table 3 summarises the different pathological
features of polymyositis and dermatomyositis,
including also inclusion body myositis charac-
teristics (see below). A not uncommon clinical
dilemma is that of a patient receiving steroids
who complains of weakness. Although a further
biopsy-a needle biopsy would be indicated in
this case-might help in differentiating steroid
from inflammatory myopathies, this is not
always the case. The most salient histopatho-
logical finding in steroid myopathy-type II
fibre atrophy-can be found as an unspecific
finding in polymyositis/dermatomyositis, and
inflammation may be absent from a biopsy
specimen of a patient with myositis receiving
steroid treatment. Clinical judgment is probably
most important in distinguishing between such
entities.
Treatment and prognosis
Prognosis depends on the form of idiopathic
inflammatory myopathy. Dermatomyositis
seems to be a more acute and aggressive disease,
but in turn responds more rapidly to immuno-
suppressive treatment. Its course tends to be
remitting with periods of improvement and
remission after treatment alternating with
occasional relapses. The frequency and severity
of relapses diminish over the years. Interes-
tingly, there are patients with dermatomyositis
who have relapses exclusively affecting the skin.
Muscle strength, creatine kinase activity, and
even successive muscle biopsy specimens are
normal. In such cases a 'silent' neoplasia, such
as prostatic gland carcinoma or low grade non-
Hodgkin's lymphoma, has to be completely
ruled out. Polymyositis, on the other hand, is a
more insidious disease and the response to
treatment slower. Treatment strategies have to
be based on these points and on pathogenetic
mechanisms. Adverse side effects must be
avoided as far as possible, while remembering
that the degree of residual weakness depends on
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the accuracy of the initial treatment. In
dermatomyositis we use high dose steroids
(1 mg/kg daily). In polymyositis we use steroids
in lower doses (0-3 mg/kg daily) together with
azathioprine (2 mg/kg daily). With patients over
70 we follow the polymyositis strategy. After
two to four months' treatment in dermatomyo-
sitis and four to six months in polymyositis the
doses are gradually tapered over one to one anda
half years. Similar schedules are followed by
other authors.9 51
There are single case reports of patients
with polymyositis/dermatomyositis treated with
cyclosporin, but results are contradictory.52 53
Only recently has the usefulness of this drug
been clearly shown in refractory cases of juvenile
dermatomyositis.54 Our own experience with
this drug is also encouraging not only in
refractory cases, but as a first choice of treat-
ment in some particular forms (aggressivejuvenile forms of dermatomyositis). Important
adjuncts to the drug treatment include a high
protein diet and isometric muscle exercise after
a brief period of bed rest. Overall mortality in
polymyositis/dermatomyositis is about 10% if
paraneoplastic forms are excluded.
Inclusion body myositis
Inclusion body myositis is currently considered
one major form of inflammatory myopathy
owing to its inflammatory exudates and the
expression of class I MHC products in some
muscle cells.9 5 It was first described in 197156
and characterised as a distinct clinical entity in
1978.57 As the diagnostic criteria are mainly
histopathological,58 there are a wide range of
clinical forms. 10 57 The most typical is that of
an old man whose only complaint is longstand-
ing predominantly distal muscle weakness, or
that of a patient with polymyositis resistant to
treatment.58 Anecdotal associations with other
diseases have been reported.61~3 The long
clinical course, the particular distal distribution
of weakness, the reported familial cases, and the
lack of response to any immunosuppressive or
antiviral treatment suggest that it is not an
inflammatory condition. Some authors suggest
that it should be considered a primary non-
inflammatory muscle disease.55 4 It is currently
managed by physiotherapy and general support.
No epidemiological data on its mortality are
available.
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